Obesity Therapy

Successful phase Ia trial results reported on anti-obesity compound

Published in Obesity and Diabetes Week, August 9th, 2004

Arena Pharmaceuticals, Inc., (ARNA) announced results from a phase Ia, single-dose clinical trial of the company's novel anti-obesity compound, APD356.

APD356 is an orally administered small molecule that is a selective 5-HT2C serotonin receptor agonist. The 5-HT2C receptor is located in an area of the brain believed to play an important role in regulating food intake and metabolism.

This first clinical study of APD356 explored the relationship among dose, concentration, and desired and undesired effects. Highlights of the study include:

1) Evidence of a pharmacologic effect on food intake was seen with a single 10 mg dose of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-08-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry